Table 1.
Targets of interest to target leukemia stem cells in AML patients.
| Target | Reference | Therapeutic approach | Stage |
|---|---|---|---|
| CD123 | [9-11] | DT388-IL3 (SL-401); anti-CD123 monoclonal antibody (CSL360) | Phase I/II |
| CD25 | [8] | Humanized anti-CD25 antibody (daclizumab), immunotoxin denileukin diftitox | Phase I/II |
| NF-kappaB | [23,26,27] | Bortezomib | Phase I/II |
| BCL-2 | [33] | Obatoclax, Sabutoclax | Phase I/II, Pre-clinical |
| DOT1L | [53] | EPZ004777 | Pre-clinical |
| LSD1 | [54] | Tranylcypromine (TCP) | Pre-Clinical |
| PRC2 complex | [56] | DZNep | Preclinical |
| IDH1/2 | [66,67] | AGI-6780, AGI-5198 | Pre-clinical |
| DNMT inhibitors | [46-47] | Decitabine, Azacitidine | Phase I/II/III |
| Mitochrondrial translation | [43] | Tigecycline | Pre-clinical |